FDA accepts AstraZeneca's fish oil-based drug Epanova for review

09/19/2013 | Reuters · PharmaTimes (U.K.)

The FDA has accepted AstraZeneca's application to market its fish oil-based drug Epanova as a treatment for severe hypertriglyceridemia. The drug was originally developed by Omthera Pharmaceuticals, which was bought by AstraZeneca this year. A decision is expected by May 5.

View Full Article in:

Reuters · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX